Navigation Links
Low-cost drug gaining favor for use in HIV-infected children in poor countries

A new systematic review highlights strong results from a single study at the center of mounting support for worldwide use of the low-cost drug Bactrim to help HIV-infected children in poor countries.

The reviewers surveyed medical literature on the preventive use of Bactrim -- one of several brand names for the generic medicine cotrimoxazole -- for children to ward off common infections that can be deadly to a person whose immune system is weakened by HIV.

Dr. Kate Grimwade, with the Heart of England National Health Service foundation trust in Birmingham, led the review of the drug and found "a significant mortality benefit."

Grimwade's review appears in the most recent issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

To be included in the Cochrane findings, a study had to be a randomized clinical trial. Grimwade's search turned up only one trial that passed that litmus test: a study of 534 HIV-positive children in Zambia.

The study found 33 percent fewer deaths in the group of children who received cotrimoxazole versus the children who were not treated with the antibiotic. The children prescribed cotrimoxazole also were hospitalized less. Those positive results held true "across the board" for children in all age groups and in different stages of HIV illness, Grimwade said.

Every medication has side effects, and the trial did uncover some adverse reactions from cotrimoxazole. Still, Grimwade said the Zambian study shows that the drug is a safe precaution against opportunistic infections in HIV-positive children.

The new review is being released as health policy makers anticipate updated recommendations on cotrimoxazole from the World Health Organization. In May 20 05, the WHO gathered HIV/AIDS experts from around the world -- including Grimwade -- to pore over the scientific evidence on the preventive use of cotrimoxazole for people with HIV.

Nine months later, Grimwade said despite concerns over drawing conclusions from one study there is now much more consensus. She said, "the new WHO guidelines will likely recommend its use in both infected adults and children."

"In the latest discussions, there's no talk of further studies. It's basically accepted now," she added. The results from the single trial are so strong, Grimwade said, that many people believe that it is unethical to use a placebo in children to further investigate the preventive use of the drug.

Dr. Marco Antônio de Ávila Vitória, a medical officer with the WHO's Department of HIV/AIDS, also said preventive use of cotrimoxazole is gaining wide acceptance.

"It's a very cheap strategy," he said, "and the drug is very available, a lot more available in many areas where antiretroviral drugs are not around."

Cotrimoxazole is not a substitute for antiretroviral treatment, but the antibiotic may be a good stopgap measure until comprehensive HIV/AIDS care is available, or a way to extend the time until a patient needs anti-retroviral drugs, Vitória said.

Vitória said many discussions at the WHO summit centered on which settings would best benefit from preventive cotrimoxazole treatment given their health care infrastructure and ability to monitor and respond to possible side effects.

The WHO updated recommendations -- scheduled to be released early this year -- will provide some guidance for countries as they make their own decisions, Vitória said.

The recommendations include guidelines on monitoring toxicity and when to begin cotrimoxazole treatment given the child's age, whether the patient has symptoms of HIV disease and the strength of the patient's immune system.


'"/>

Source:Center for the Advancement of Health


Related biology news :

1. Underdogs in the understory: Study suggests nature favors rarer trees
2. Study finds evolution doesnt always favor bigger animals
3. Some like it hot: Worms at deep-sea vents favor a fiery 45-55°C
4. The loss of a protein favors lung tumor growth
5. Zinc supplements safe for HIV-infected children
6. HIV-infected adults in Botswana respond positively to ARV therapy public treatment program
7. New study shows benefit of early therapy in HIV-infected infants
8. Meth promotes spread of virus in HIV-infected users
9. $5.1 billion would save 6 million children
10. Genetically engineered animals help in scientific research that may benefit children
11. Genes linked to treatment resistance in children with leukemia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
Breaking Biology Technology: